CORDIS
EU research results

CORDIS

English EN
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Objective

AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, especially compounds with novel modes of action. Finding and developing such compounds represents a huge scientific challenge, one that requires the collaboration of stakeholders bringing many different kinds of expertise. The world is coming together to tackle this issue and public-private partnerships represent an attractive way to hasten the pace and increase the probability of successfully identifying and developing novel antibiotics.

Under the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials-NOW (GNA NOW) consortium pledges to a 6-years commitment to bring together key European academic and private experts in antibiotic discovery and development in order to support and manage a portfolio of novel mode of action drugs against Gram-negative bacteria. Starting with three initial compounds/series, dedicated project teams will work together to define and execute the most efficient project plans. The consortium will put in place robust governance and management structures to ensure that the most promising compounds are pursued diligently. Ultimately, the goal of GNA NOW is to progress one compound through completion of phase I studies plus one compound reaching Investigational New Drug (IND) stage and/or up to two compounds reaching clinical development candidate stage.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

STICHTING LYGATURE

Address

Jaarbeursplein 6
3521 Al Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 620 681,25

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

EVOTEC INTERNATIONAL GMBH

Germany

NOSOPHARM

France

EU Contribution

€ 4 069 500

BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE

France

EU Contribution

€ 308 896,25

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

Germany

EU Contribution

€ 1 268 750

NORTH BRISTOL NATIONAL HEALTH SERVICE TRUST

United Kingdom

EU Contribution

€ 2 422 556,25

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 430 523,75

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 185 662,50

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 1 198 125

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 1 495 300

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 300 000

Project information

Grant agreement ID: 853979

Status

Ongoing project

  • Start date

    1 July 2019

  • End date

    30 June 2025

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 31 415 987

  • EU contribution

    € 12 299 995

Coordinated by:

STICHTING LYGATURE

Netherlands